Strategic Acquisition Sanifit has recently been involved in high-profile acquisitions and partnerships with Vifor Pharma, indicating a market trajectory toward strategic collaborations. Sales opportunities exist in positioning SNF472 within co-development or license deals with nephrology and cardio-renal portfolios.

Clinical Milestones With SNF472 in Phase II programs for ESRD and calciphylaxis, there is a clear near-term opportunity to engage clinicians and payers around trial data, expansion plans, and potential benchmark endpoints to support reimbursement discussions and clinical adoption.

Clinical Need The focus on vascular calcification disorders in end-stage kidney disease presents a well-defined market need. Promote SNF472 as a first-in-class approach to calcification inhibition to coordinate discussions with dialysis centers, transplant programs, and nephrology networks.

Funding Momentum A substantial funding history and a recent €36.6M Series C signal strong investor confidence and a readiness to scale. Leverage this to pursue co-financing, milestone-based partnerships, and joint development agreements with larger biopharma seeking cardio-renal assets.

Global Footprint With a US subsidiary and international interest, there are multiple regional sales angles—from North American clinical access programs to European regulatory and market access strategies—targeting nephrology and cardiovascular care ecosystems for SNF472 adoption.